Bullfrog AI Holdings, Inc. Common Stock (BFRG) Total Equity: History & Chart

Bullfrog AI Holdings, Inc. Common Stock(BFRG)

Medical - Healthcare Information Services · Gaithersburg, MD

$0.58-0.02 (-3.00%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

9 employees

www.bullfrogai.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Vininder Singh

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $6.99M with QoQ Growth of +42.98%. Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

BFRG Total Equity

$6.99M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $6.99M.

+792.42% over 10Y

BFRG P/B Ratio

Full P/B Ratio page

P/B Ratio

BFRG P/B Ratio Chart

1.53

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T13:35:45.321Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$6.99M	+42.98%	+219.33%
Q1 FY2026Period end 2026-03-31	$4.89M	+128.75%	+50.53%
Q4 FY2025Period end 2025-12-31	$2.14M	+9.91%	(56.96%)
Q3 FY2025Period end 2025-09-30	$1.94M	(11.17%)	(49.16%)
Q2 FY2025Period end 2025-06-30	$2.19M	(32.60%)	(59.37%)
Q1 FY2025Period end 2025-03-31	$3.25M	(34.60%)	(52.29%)
Q4 FY2024Period end 2024-12-31	$4.96M	+29.83%	+91.48%
Q3 FY2024Period end 2024-09-30	$3.82M	(29.00%)	+1.44%
Q2 FY2024Period end 2024-06-30	$5.39M	(20.86%)	+9.89%
Q1 FY2024Period end 2024-03-31	$6.80M	+162.49%	+47.16%
Q4 FY2023Period end 2023-12-31	$2.59M	(31.22%)	N/A
Q3 FY2023Period end 2023-09-30	$3.77M	(23.09%)	N/A
Q2 FY2023Period end 2023-06-30	$4.90M	+5.98%	N/A
Q1 FY2023Period end 2023-03-31	$4.62M	N/A	N/A
Q4 FY2022Period end 2022-12-31	($3.06M)	(26.68%)	N/A
Q3 FY2022Period end 2022-09-30	($2.41M)	(27.54%)	N/A
Q2 FY2022Period end 2022-06-30	($1.89M)	N/A	N/A
Q4 FY2021Period end 2021-12-31	($1.01M)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.